<DOC>
	<DOCNO>NCT02254707</DOCNO>
	<brief_summary>To assess antiviral effect , safety pharmacokinetics rise dos 10 mg , 20 mg , 40 mg , 60 mg , 80 mg , 100 mg , 150 mg , 200 mg , 300 mg , 450 mg , 650 mg , 900 mg oral BILB 1941 ZW administer Q8H polyethyleneglycol 400 ( PEG 400 ) : distilled water : Tromethamine ( TRIS ) drink solution five day patient chronic HCV genotype 1 infection</brief_summary>
	<brief_title>Evaluation Antiviral Pharmacodynamic Effect , Safety , Pharmacokinetics Escalating Doses BILB 1941 ZW Patients With Chronic Hepatitis C Genotype 1 Virus Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>1 . Adult males 18 65 year 2 . Written inform consent consistent ICH ( International Conference Harmonisation ) /GCP ( Good Clinical Practice ) local legislation give prior study procedure 3 . Chronic HCV infection demonstrate positive HCV IgG Antibody 4 . HCV genotype 1 confirmed central laboratory test Visit 2 5 . Liver biopsy consistent active Hepatitis C virus ( HCV ) infection obtain within last 24 month show minimal mild liver fibrosis without cirrhosis ( Ishak Metavir grade &lt; = 2 ) 6 . HCV ribonucleic acid ( RNA ) load great 100,000 IU RNA per ml serum screen 7 . Willing abstain alcohol screening , treatment completion study ( visit 11 ) 1 . Males use adequate form contraception ( condom , sterilisation least 6 month post operation ) case partner childbearing potential use adequate form contraception ( hormonal contraceptive , oral injectable/implantable , intrauterine device ( IUD ) . 2 . Any additional plausible cause chronic liver disease , include presence virus know suspected cause hepatitis 3 . Evidence decompensated liver disease : ascites , portal hypertension hepatic encephalopathy 4 . Positive test human immunodeficiency virus ( HIV ) Hepatitis B surface ( HBs ) antigen screen 5 . Current alcohol drug abuse , history , within past twelve ( 12 ) month . All patient must abstain alcohol enrolment completion study ( visit 11 ) . 6 . Any concurrent medical illness disease require treatment concomitant medication 7 . History malignancy ( except previously cure squamous cell basal cell carcinoma ) 8 . Usage investigational drug within thirty ( 30 ) day prior enrolment 5 halflives , whichever longer ; plan usage investigational drug course current study 9 . Patients treat interferon and/or ribavirin within 6 month prior screen 10 . Planned concurrent usage pharmacological therapy screening , trial period , include antiviral therapy vaccination 11 . Known hypersensitivity drug excipients 12 . Patients one follow laboratory value screen : Alanine transaminase ( ALT ) Aspartate transaminase ( AST ) &gt; 2.5 x upper limit normal ( ULN ) ( screen last 3 month screen demonstrate least 2 determination ) Total bilirubin &gt; 1x ULN Alkaline phosphatase &gt; 1.5x ULN Prothrombin time ( INR , prolong ) &gt; 1.5 Platelet count &lt; 100,000 / mm3 Hemoglobin &lt; 10.5 g/dL White blood cell count &lt; 2,000 / mm3 13 . Patients clinically significant laboratory abnormality base investigator 's medical assessment screen 14 . Positive urine test drug abuse screen 15 . Patients know Gilbert 's disease 16 . Prior randomisation active treatment BILB 1941 ZW dose group 3 9 trial , previous retreatment base amendment 2 . To support selection , center receive list placebo patient previous dose level , however , center separately 17 . Inability comply protocol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>